Cargando…

Licensed Anti-Microbial Drugs Logical for Clinical Trials against Pathogens Currently Suspected in Alzheimer’s Disease

There is now considerable evidence that several infectious agents (viruses, bacteria, or parasites) may play a contributing role in the development of Alzheimer’s disease (AD). The six primary suspects are herpes viruses, spirochetal bacteria, Chlamydia pneumoniae, Porphyromonas gingivalis, mycobact...

Descripción completa

Detalles Bibliográficos
Autor principal:	Norins, Leslie C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003809/ https://www.ncbi.nlm.nih.gov/pubmed/33804679 http://dx.doi.org/10.3390/antibiotics10030327

Ejemplares similares

Repurposing Licensed Drugs for Use Against Alzheimer’s Disease
por: Norins, Leslie C.
Publicado: (2021)

The Legislative Approach and System Improvement of China’s Compulsory Licensing for Drug Patents
por: Cao, Zhang, et al.
Publicado: (2021)

Why Open Drug Discovery Needs Four Simple Rules for Licensing Data and Models
por: Williams, Antony J., et al.
Publicado: (2012)

Microbial Dark Matter Investigations: How Microbial Studies Transform Biological Knowledge and Empirically Sketch a Logic of Scientific Discovery
por: Bernard, Guillaume, et al.
Publicado: (2018)

Why should cell biologists study microbial pathogens?
por: Welch, Matthew D.
Publicado: (2015)

The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs
por: Li, Yanbai, et al.
Publicado: (2023)

Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective
por: Bindu, Samik, et al.
Publicado: (2020)

Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020
por: Arondekar, Bhakti, et al.
Publicado: (2022)

Challenges and Prospects for Integrating the Assessment of Health Impacts in the Licensing Process of Large Capital Project in Brazil
por: de Souza Hacon, Sandra, et al.
Publicado: (2018)

Open drug discovery in Alzheimer's disease
por: Axtman, Alison D., et al.
Publicado: (2023)

Anti-amyloid: An antibody to cure Alzheimer’s or an attitude
por: Osborne, Olivia M., et al.
Publicado: (2023)

Converging multi-modality datasets to build efficient drug repositioning pipelines against Alzheimer’s disease and related dementias
por: Yin, Zheng, et al.
Publicado: (2022)

Licensed Dengue Vaccine: Public Health Conundrum and Scientific Challenge
por: Halstead, Scott B.
Publicado: (2016)

Allele-specific expression elucidates cis-regulatory logic
por: Delbare, Sofie Y. N., et al.
Publicado: (2018)

The neuroprotective effects of the anti-diabetic drug linagliptin against Aβ-induced neurotoxicity
por: Lin, Chih-Li, et al.
Publicado: (2016)

Tiny Gatekeepers: Microbial Control of Host Drug Transporters
por: Kyaw, Than S., et al.
Publicado: (2022)

Historic recurrences in medicinal chemistry: nature-inspired structures as a new opportunity for novel multi-target anti-Alzheimer’s drugs
por: Piemontese, Luca
Publicado: (2023)

Aminopeptidase A and dipeptidyl peptidase 4: a pathogenic duo in Alzheimer’s disease?
por: Checler, Frédéric, et al.
Publicado: (2022)

Gene-Regulatory Logic to Induce and Maintain a Developmental Compartment
por: Milán, Marco
Publicado: (2015)

Using a Logic Model to Direct Backward Design of Curriculum
por: Loberti, Aria Mia, et al.
Publicado: (2018)

Targeting abnormal metabolism in Alzheimer's disease: The Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study
por: Desai, Rishi J., et al.
Publicado: (2020)

DNA damage and neurodegeneration: the unusual suspect
por: Stein, Daniel, et al.
Publicado: (2017)

Anti-amyloid therapies for Alzheimer disease: finally, good news for patients
por: Ramanan, Vijay K., et al.
Publicado: (2023)

Administration of pre/probiotics with conventional drug treatment in Alzheimer’s disease
por: Hort, Jakub, et al.
Publicado: (2019)

Tetrahydrohyperforin: a neuroprotective modified natural compound against Alzheimer's disease
por: Montecinos-Oliva, Carla, et al.
Publicado: (2015)

Direct oral anticoagulants: a new therapy against Alzheimer’s disease?
por: Grossmann, Klaus
Publicado: (2021)

Heparan sulfate proteoglycans and heparanases in Alzheimer's disease: current outlook and potential therapeutic targets
por: Lorente-Gea, Laura, et al.
Publicado: (2017)

4-1BB Agonism as a strategy to license immune checkpoint blockade in glioblastoma
por: Woroniecka, Karolina, et al.
Publicado: (2020)

Biomarker-guided drug therapy: personalized medicine for treating Alzheimer’s disease
por: Syal, Charvi, et al.
Publicado: (2021)

Neuromuscular function in experimental disuse – a prime suspect?
por: Soendenbroe, Casper
Publicado: (2022)

Chemical exposures and suspected impact on Gulf War Veterans
por: Elhaj, Rami, et al.
Publicado: (2023)

The hidden variables problem in Alzheimer's disease clinical trial design
por: Liyanage, S. Imindu, et al.
Publicado: (2018)

Alzheimer's disease in Down syndrome: An overlooked population for prevention trials
por: Strydom, André, et al.
Publicado: (2018)

Recruiting to preclinical Alzheimer's disease clinical trials through registries
por: Grill, Joshua D.
Publicado: (2017)

Mobile and pervasive computing technologies and the future of Alzheimer’s clinical trials
por: Doraiswamy, P. Murali, et al.
Publicado: (2018)

Reversing Alzheimer's disease dementia with clemastine, fingolimod, or rolipram, plus anti‐amyloid therapy
por: Fessel, Jeffrey
Publicado: (2022)

Bayes analysis supports null hypothesis of anti‐amyloid beta therapy in Alzheimer's disease
por: Richard, Edo, et al.
Publicado: (2021)

Initial failures of anti-tau antibodies in Alzheimer’s disease are reminiscent of the amyloid-β story
por: Imbimbo, Bruno P., et al.
Publicado: (2022)

Fighting microbial drug resistance: a primer on the role of evolutionary biology in public health
por: Perron, Gabriel G, et al.
Publicado: (2015)

Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development
por: Rabinovici, Gil D., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_lns26q9c7j3317nbepnec0ihma